Regular RSV testing in older patients with respiratory symptoms is relatively low, and targeted efforts are needed to increase RSV testing in this group.
Updated RSV vaccine recommendations for older adults replace last year’s guidance to simplify RSV vaccine decision-making for clinicians and the public.
Modeling excess risk using viral positivity data provides a comprehensive estimation of RSV hospitalization burden and associated costs compared with ICD codes.
Paired serology testing, standard-of-care swabs, and separate testing of nasopharyngeal and oropharyngeal swabs improved RSV diagnosis in hospitalized adults.